Lisata Therapeutics (LSTA) Cost of Revenue (2016 - 2017)
Historic Cost of Revenue for Lisata Therapeutics (LSTA) over the last 8 years, with Q1 2017 value amounting to $8.0 million.
- Lisata Therapeutics' Cost of Revenue rose 2912.51% to $8.0 million in Q1 2017 from the same period last year, while for Mar 2017 it was $33.0 million, marking a year-over-year increase of 4314.64%. This contributed to the annual value of $31.1 million for FY2016, which is 5445.41% up from last year.
- According to the latest figures from Q1 2017, Lisata Therapeutics' Cost of Revenue is $8.0 million, which was up 2912.51% from $9.2 million recorded in Q4 2016.
- In the past 5 years, Lisata Therapeutics' Cost of Revenue registered a high of $9.2 million during Q4 2016, and its lowest value of $2.4 million during Q1 2013.
- Its 5-year average for Cost of Revenue is $5.2 million, with a median of $4.2 million in 2013.
- Its Cost of Revenue has fluctuated over the past 5 years, first tumbled by 2058.86% in 2013, then soared by 8489.22% in 2016.
- Over the past 5 years, Lisata Therapeutics' Cost of Revenue (Quarter) stood at $3.3 million in 2013, then rose by 24.49% to $4.2 million in 2014, then surged by 48.51% to $6.2 million in 2015, then soared by 49.53% to $9.2 million in 2016, then decreased by 13.01% to $8.0 million in 2017.
- Its last three reported values are $8.0 million in Q1 2017, $9.2 million for Q4 2016, and $8.6 million during Q3 2016.